A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT04849715 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped business decision; no enrolled patients

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: parsaclisib
DRUG: rituximab
DRUG: bendamustine
DRUG: Placebo

Sponsor

Incyte Corporation